ORKA
Oruka Therapeutics, Inc.
Set alert
96.87 USD +0.22 +0.23%
94.75 Day range 97.60
26.19 52-week range 113.08
- YTD
- +219.60%
- 1 year
- +244.61%
- Open
- 94.87
- Prev close
- 96.65
- Mkt cap
- 6.41B
- Vol
- 634.04K
- Avg vol
- 894.42K
- EPS
- -2.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.75
- High
- 97.60
- Forward P/E
- -33.85
- Beta
- -0.11
- Short ratio
- 5.86
- Inst. own
- 116.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 88.63
- 200-d avg
- 68.91
- 1y target
- 156.17
Key statistics
- Market cap
- 6.41B
- Enterprise value
- 5.53B
- Trailing P/E
- 0.00
- Forward P/E
- -33.85
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.32
- EPS (TTM)
- -2.04
- Beta
- -0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -65.03M
- Total cash
- 873.56M
- Total debt
- 2.55M
- Return on equity
- -18.23%
- Shares outstanding
- 66.21M
- Short % of float
- 13.44%
- 50-day average
- 88.63
- 200-day average
- 68.91
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 156.17 +61.2% upside
Now 96.87
- Target (low)
- 117.00
- Target (mean)
- 156.17
- Target (high)
- 200.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.61832.
Financials — quick view
ORKA Revenue — quarterly 0
ORKA Net income — quarterly -41.21M
ORKA EPS — quarterly -0.55
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.59959 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.51249 | -0.55 | -0.04 | -7.32% |
| May 13, 2026 | Mar 31, 2026 | -0.54692 | -0.48 | +0.07 | +12.24% |
| Mar 12, 2026 | Dec 31, 2025 | -0.61 | -0.45 | +0.16 | +26.23% |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -0.55 | +0.01 | +1.79% |
| Aug 11, 2025 | Jun 30, 2025 | -0.48 | -0.46 | +0.02 | +4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Guggenheim | reit | Buy | Buy |
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Sep 24, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- orukatx.com
News
- Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
- Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target
- HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
- Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
- Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript
- Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
- Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
- Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday
- Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Your note
Sign in to keep a note on ORKA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGARWAL ARJUN | Officer | Sale | Oct 11, 2026 | 14,219 |
| DAMBKOWSKI CARL | Director | Sale | Jun 11, 2026 | 38,743 |
| EDWARDS LARRY TODD | Officer | Stock Award(Grant) | Aug 23, 2026 | 100,000 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 30, 2026 | 0 |
| GONCALVES JOANA | Officer | Sale | Sep 14, 2026 | 31,771 |
| KLEIN LAWRENCE OTTO | Chief Executive Officer | Sale | Sep 14, 2026 | 923,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.68% | 9,057,645 | 877.41M | Jun 29, 2026 |
| Blackrock Inc. | 7.54% | 4,990,181 | 483.40M | Jun 29, 2026 |
| Venrock Adviser, LLC | 6.27% | 4,148,428 | 401.86M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 5.60% | 3,705,262 | 358.93M | Jun 29, 2026 |
| Capital World Investors | 5.14% | 3,401,639 | 329.52M | Jun 29, 2026 |
| RTW Investments LP | 4.74% | 3,139,030 | 304.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.60% | 1,724,692 | 167.07M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 1,614,957 | 156.44M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.31% | 1,527,592 | 147.98M | Sep 29, 2026 |
| New Economy Fund | 2.00% | 1,323,308 | 128.19M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 1,304,825 | 126.40M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.95% | 1,294,135 | 125.36M | Aug 30, 2026 |